GUD Share Price Performance

GUD Community Fair Values

Knight Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Paladin Acquisition And New Launches Will Expand Market Presence
Key Takeaways Acquisitions and expanded partnerships bolster Knight's Canadian and oncology revenue, enhancing stability and growth prospects. Product launches and strategic contracts in Latin America are anticipated to drive future revenue and improve margins.
View narrative
CA$7.91
FV
24.1% undervalued intrinsic discount
7.66%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
3 days ago author updated this narrative
Your Fair Value
CA$
Current Price
CA$6.0014.9% undervalued intrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

View all narratives

Recent GUD News & Updates

Knight Therapeutics' (TSE:GUD) Solid Profits Have Weak Fundamentals

May 16

Paladin Acquisition And New Launches Will Expand Market Presence

May 10 Acquisitions and expanded partnerships bolster Knight's Canadian and oncology revenue, enhancing stability and growth prospects.

Knight Therapeutics Inc. Competitors

View more competitors

Canadian Market Performance

0.9%

7.2%

16.9%

6.5%

In the last week, the market has stayed flat, however the Materials sector stood out, gaining 4.6%. More promisingly, the market is up 17% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

Knight Therapeutics Stock Price

GUD Share Price Performance

GUD Community Fair Values

Paladin Acquisition And New Launches Will Expand Market Presence

Recent GUD News & Updates

Knight Therapeutics' (TSE:GUD) Solid Profits Have Weak Fundamentals

Consensus EPS estimates increase by 101%

Paladin Acquisition And New Launches Will Expand Market Presence

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q1, 2025 Results on May 08, 2025

President exercised options to buy CA$298k worth of stock.

Knight Therapeutics Inc. Announces Launch of Minjuvi® (Tafasitamab) in Mexico

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. Competitors

🎢 Opportunities In The Turbulent Transition To Greener Energy

🤖 A.I. Enters the “Show Me The Money” Phase